Introduction C.H. Boehringer Sohn AG & Co. KG is a holding company that specializes in the production of pharmaceutical products. The company's prescription drugs are used to treat various human diseases such as respiratory, cardiovascular, gastrointestinal, and central nervous system disorders, including HIV infection and cancer. Established in 1885, C.H. Boehringer Sohn AG & Co. KG is headquartered in Ingelheim am Rhein, Germany. |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 146 |
Monoclonal antibody | 29 |
Unknown | 19 |
Antibody drug conjugate (ADC) | 12 |
Bispecific antibody | 9 |
Target |
Mechanism IL-36R inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date01 Sep 2022 |
Target |
Mechanism DPP-4 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date27 Jan 2020 |
Target |
Mechanism PD-1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date26 Dec 2019 |
Start Date06 Aug 2024 |
Sponsor / Collaborator |
Start Date27 Jul 2024 |
Sponsor / Collaborator |
Start Date01 Jul 2024 |
Sponsor / Collaborator Incyte Corp. [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Nintedanib esylate ( CSF-1R x FGFRs x FLT3 x PDGFR x VEGFR ) | Non-Small Cell Lung Cancer More | Approved |
Empagliflozin/Linagliptin/Metformin Hydrochloride ( DPP-4 x PRKAB1 x SGLT2 ) | Diabetes Mellitus, Type 2 More | Approved |
Meloxicam ( COX-1 x COX-2 ) | Periarthritis More | Approved |
Pimobendan ( cGMP-PDE ) | Heart Failure More | Approved |
Ipratropium Bromide ( mAChRs ) | Bronchitis, Chronic More | Approved |